HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort

Executive Summary

Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.

You may also be interested in...



Ginger, Mushroom, Aloe Supplements Get US FDA Warnings For Disease Claims

Three firms were warned after FDA inspectors reviewed their websites or social media posts. No facility inspections nor warnings about GMP problems were noted in the letters.

Bloom In US Demand For Immunity Supplements Prompts Abbott, Star Nutra And PRTCL Launches

Abbott expands Pedialyte children’s line with adult products including Immune Support beverage in response to consumer demands for nutritional supplements to support immune health; Star Nutra introduces gummy immunity supplements; and PRTCL has a women’s immune-boost product.

Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

Topics

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel